[Progestogen contraception using chlormadinone acetate in women presenting high vascular risk. (A gynecoendocrine, metabolic and vascular study)].
Pelissier
C
C
Basdevant
A
A
Conard
J
J
Egloff
M
M
Husson
T
T
Guyenne
T T
TT
D001695:Biology; D002319:Cardiovascular System; D002715:Chlormadinone Acetate; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D019049:Developed Countries; D004194:Disease; D004467:Economics; D004703:Endocrine System; D005060:Europe; D005069:Evaluation Studies as Topic; D005193:Family Planning Services; D005602:France; D006728:Hormones; D008660:Metabolism; D010827:Physiology; D012102:Reproductive Control Agents; D012106:Research; D013672:Technology
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D006728:Hormones; D012102:Reproductive Control Agents; D002715:Chlormadinone Acetate
Biology; Cardiovascular Effects; Chlormadinone Acetate; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen--contraindications; Contraceptive Agents, Female; Contraceptive Agents, Progestin--indications; Contraceptive Agents--contraindications; Contraceptive Agents--indications; Developed Countries; Diseases; Economic Factors; Endocrine System; Europe; Evaluation; Family Planning; France; Hormones; Mediterranean Countries; Metabolic Effects; Physiology; Reproductive Control Agents; Research And Development; Research Methodology; Reversibility; Technology; Western Europe